Physician profile
Eric D Allen
NPI 1033528997
$981.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.96 · 2022: $418 · 2023: $434 · 2024: $29.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.24 | 2022-2024 | |
| Lilly USA, LLC | $127.42 | 2021-2023 | Mounjaro, Reyvow, Emgality |
| Novo Nordisk INC | $70.80 | 2022-2023 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $63.43 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $46.73 | 2021 | |
| Pfizer INC. | $41.53 | 2023 | |
| Avanir Pharmaceuticals, INC. | $30.96 | 2022 | |
| Neos Therapeutics, Lp | $30.29 | 2022-2023 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $27.47 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $24.07 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $24.00 | 2022 | |
| Abbott Laboratories | $23.10 | 2023 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $21.76 | 2023 | |
| Tris Pharma INC | $15.99 | 2023 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $14.44 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.76 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.